ERCC2

General transcription and DNA repair factor IIH helicase subunit XPD · P18074 · ERCC2 on Sugi Atlas →

5,846 patent compounds predicted against ERCC2, 4,876 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Seliciclib (SCHEMBL94728)	1.00	1/20
(Rs)-Roscovitine (SCHEMBL172593)	1.00	1/20
Bms-387032 (SCHEMBL187401)	1.00	1/20
Danusertib (SCHEMBL466509)	1.00	1/20
Milciclib (SCHEMBL619139)	1.00	1/20
Tak-901 (SCHEMBL645679)	1.00	1/20
Zotiraciclib (SCHEMBL823947)	1.00	1/20
Pf-00562271 (SCHEMBL1206959)	1.00	1/20
Pf-03758309 (SCHEMBL1369342)	1.00	1/20
Defactinib (SCHEMBL1627234)	1.00	1/20
Rgb-286638 (SCHEMBL1178926)	0.99	1/20
Tak-901 (SCHEMBL646980)	0.98	1/20
Tak-901 (SCHEMBL2123148)	0.98	1/20
Defactinib (SCHEMBL1626017)	0.98	1/20
Tak-901 (SCHEMBL2122890)	0.97	1/20
Tak-901 (SCHEMBL2125658)	0.97	1/20
Tak-901 (SCHEMBL2125119)	0.96	1/20
Tak-901 (SCHEMBL2121299)	0.93	1/20
Tak-901 (SCHEMBL2121923)	0.93	1/20
Tak-901 (SCHEMBL2122190)	0.92	1/20

Clinical trials — most relevant to ERCC2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer	PHASE2	COMPLETED
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy	PHASE2	COMPLETED
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction	PHASE2	COMPLETED
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	PHASE2	COMPLETED
Satraplatin and Prednisone to Treat Prostate Cancer	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer	PHASE2	UNKNOWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer	PHASE2	COMPLETED
Olaparib in People With Malignant Mesothelioma	PHASE2	COMPLETED
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer	PHASE2	COMPLETED
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	PHASE1	COMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.	nan	UNKNOWN
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel	nan	COMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate	nan	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ERCC2 binder may also engage these)

Protein	Name	Similarity
Q60452	—	1.000	Q60452 →
O08811	—	1.000	O08811 →
A6QLJ0	—	1.000	A6QLJ0 →
P26659	—	0.992	P26659 →
Q8W4M7	—	0.987	Q8W4M7 →
P06839	—	0.983	P06839 →
Q55G81	—	0.981	Q55G81 →
NAT10	RNA cytidine acetyltransferase	0.979	landscape →
A1CJ34	—	0.977	A1CJ34 →
P24785	—	0.974	P24785 →
Q2U587	—	0.974	Q2U587 →
Q5BGR9	—	0.973	Q5BGR9 →
Q9CZP5	—	0.973	Q9CZP5 →
PC	Pyruvate carboxylase, mitochondrial	0.973	landscape →
Q29G21	—	0.972	Q29G21 →
Q8K224	—	0.972	Q8K224 →
Q0CUU1	—	0.972	Q0CUU1 →
Q9LNC5	—	0.972	Q9LNC5 →
F4JWP9	—	0.971	F4JWP9 →
Q9VUV9	—	0.971	Q9VUV9 →
P45437	—	0.971	P45437 →
A2QY22	—	0.971	A2QY22 →
F1R345	—	0.971	F1R345 →
Q8RXF8	—	0.971	Q8RXF8 →
Q4WK80	—	0.970	Q4WK80 →
E9EV02	—	0.970	E9EV02 →
PRMT5	Protein arginine N-methyltransferase 5	0.970	landscape →
Q2HB00	—	0.970	Q2HB00 →
E7F8F4	—	0.970	E7F8F4 →
P52873	—	0.970	P52873 →